Literature DB >> 34391586

Medically treated opioid overdoses among New Jersey Medicaid beneficiaries: Rapid growth and complex comorbidity amid growing fentanyl penetration.

Stephen Crystal1, Molly Nowels2, Mark Olfson3, Hillary Samples4, Arthur Robinson Williams5, Peter Treitler6.   

Abstract

OBJECTIVE: Medically treated opioid overdoses identify a population at high risk of subsequent mortality and need for treatment. This study reports on medically treated opioid overdose trends in a state with rapid fentanyl spread.
METHODS: We conducted stratified trend analysis of medically treated overdose due to heroin, synthetic opioids, methadone, or other natural opioids among New Jersey Medicaid beneficiaries aged 12-64 years (2014-2019); evaluated associations with demographics and co-occurring conditions; and examined trends in fentanyl penetration in suspected heroin seizures from New Jersey State Police data.
RESULTS: Overdose risk more than tripled from 2014 to 2019, from 120.5 to 426.8 per 100,000 person-years, respectively. Increases primarily involved heroin and synthetic opioids and were associated with co-occurring alcohol and other non-opioid drug disorders, major depressive disorder, and hepatitis C. Concurrent changes in the drug exposure environment (2015-2019) included an increase in fentanyl penetration (proportion of suspected heroin seizures that included fentanyls) from 2% to 80%, and a decrease in the proportion of Medicaid beneficiaries who received opioid analgesic prescriptions from 23% to 13%.
CONCLUSION: Results document a rapid increase in overdose risk among individuals with opioid use disorder in an environment in which fentanyl is highly prevalent, and highlight the need for intensified services and engagement of non-treatment seekers, and integrated models to address multiple co-occurring conditions and risk factors.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Comorbidity; Fentanyl; Medicaid; Opioid; Overdose; Policy

Mesh:

Substances:

Year:  2021        PMID: 34391586      PMCID: PMC8664984          DOI: 10.1016/j.jsat.2021.108546

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  27 in total

1.  The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis.

Authors:  Daniel Ciccarone
Journal:  Int J Drug Policy       Date:  2019-02-02

2.  Drug Overdose Deaths Involving Fentanyl, 2011-2016.

Authors:  Merianne R Spencer; Margaret Warner; Brigham A Bastian; James P Trinidad; Holly Hedegaard
Journal:  Natl Vital Stat Rep       Date:  2019-03

3.  Experiences of three states implementing the Medicaid health home model to address opioid use disorder-Case studies in Maryland, Rhode Island, and Vermont.

Authors:  Lisa Clemans-Cope; Jane B Wishner; Eva H Allen; Nicole Lallemand; Marni Epstein; Brenda C Spillman
Journal:  J Subst Abuse Treat       Date:  2017-10-06

4.  Opioid Abuse And Poisoning: Trends In Inpatient And Emergency Department Discharges.

Authors:  Dario Tedesco; Steven M Asch; Catherine Curtin; Jennifer Hah; Kathryn M McDonald; Maria P Fantini; Tina Hernandez-Boussard
Journal:  Health Aff (Millwood)       Date:  2017-10-01       Impact factor: 6.301

5.  Risk Factors of Prescription Opioid Overdose Among Colorado Medicaid Beneficiaries.

Authors:  Piyameth Dilokthornsakul; Gina Moore; Jonathan D Campbell; Robert Lodge; Cathy Traugott; Judy Zerzan; Richard Allen; Robert L Page
Journal:  J Pain       Date:  2015-12-22       Impact factor: 5.820

6.  Must-access prescription drug monitoring programs and the opioid overdose epidemic: The unintended consequences.

Authors:  Bokyung Kim
Journal:  J Health Econ       Date:  2020-11-26       Impact factor: 3.883

7.  Drugs Most Frequently Involved in Drug Overdose Deaths: United States, 2011-2016.

Authors:  Holly Hedegaard; Brigham A Bastian; James P Trinidad; Merianne Spencer; Margaret Warner
Journal:  Natl Vital Stat Rep       Date:  2018-12

8.  Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.

Authors:  Perrine Roux; Maria A Sullivan; Julien Cohen; Lionel Fugon; Jermaine D Jones; Suzanne K Vosburg; Ziva D Cooper; Jeanne M Manubay; Shanthi Mogali; Sandra D Comer
Journal:  Pain       Date:  2013-05-07       Impact factor: 6.961

9.  Depression and Buprenorphine Treatment in Patients with Non-cancer Pain and Prescription Opioid Dependence without Comorbid Substance Use Disorders.

Authors:  Jeffrey F Scherrer; Joanne Salas; Richard Grucza; Mark D Sullivan; Patrick J Lustman; Laurel A Copeland; Jane C Ballantyne
Journal:  J Affect Disord       Date:  2020-09-28       Impact factor: 4.839

10.  Adverse health effects of abuse-deterrent opioids: Evidence from the reformulation of OxyContin.

Authors:  David Beheshti
Journal:  Health Econ       Date:  2019-11-12       Impact factor: 3.046

View more
  3 in total

1.  Opioid overdose survivors: Medications for opioid use disorder and risk of repeat overdose in Medicaid patients.

Authors:  Stephen Crystal; Molly Nowels; Hillary Samples; Mark Olfson; Arthur Robin Williams; Peter Treitler
Journal:  Drug Alcohol Depend       Date:  2022-01-10       Impact factor: 4.492

2.  Longitudinal analysis of the prevalence and correlates of heavy episodic drinking and self-reported opioid use among a national cohort of patients with HIV.

Authors:  Benjamin J Oldfield; Yu Li; Rachel Vickers-Smith; Declan T Barry; Stephen Crystal; Kirsha S Gordon; Robert D Kerns; Emily C Williams; Brandon D L Marshall; E Jennifer Edelman
Journal:  Alcohol Clin Exp Res       Date:  2022-03-16       Impact factor: 3.928

3.  Comorbid Affective and Substance Use Disorders of Medicaid/Medicare Beneficiaries at an Opioid Treatment Program Serving Small Urban and Rural Communities.

Authors:  Jamey J Lister; Guijin Lee; Jennifer D Ellis; Emily Pasman; Elizabeth Agius; Stella M Resko
Journal:  Front Psychiatry       Date:  2022-05-02       Impact factor: 5.435

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.